Tesamorelin in Sweden: import rules

In Sweden, tesamorelin has no marketing authorisation. The FDA-approved brand Egrifta was never licensed in the EU after Theratechnologies withdrew the European marketing-authorisation application in June 2012^[1]. That means a private individual cannot simply order tesamorelin from a US pharmacy and have it shipped to a Swedish address: Swedish Customs prohibits private persons from receiving any medicine dispatched from a country outside the European Economic Area^[2].

This article covers the Swedish customs rule, the regulatory history that created the gap, the narrow named-patient route that does exist, and the grey-market reality that operates in the gap between the rules and what vendors actually ship.

What the Swedish Customs rule actually says

The Swedish Customs Agency (Tullverket) states on its online-shopping guidance page that "as a private individual, you may not receive medicines sent to you from a country outside the European Economic Area (EEA)"^[2]. The rule applies regardless of the type of medicine. There is no personal-use exemption for pharmaceuticals, and no quantity threshold below which the rule stops applying. Tesamorelin supplied from US research-chemical vendors or US compounding pharmacies falls squarely inside this prohibition.

Shipments that customs officers flag as medicines and that originate from outside the EEA can be seized at the border. The importer may face an administrative process to challenge the seizure, but there is no reliable right of return for packages held at the border. The Swedish Medical Products Agency (Läkemedelsverket) guidance warns that products purchased outside licensed EEA pharmacies carry elevated risks of adulteration and incorrect dosing.

The rule has a further dimension for controlled substances: narcotics and doping agents are completely prohibited from any source, including from within the EEA. Tesamorelin is not currently classified as a narcotic or doping agent in Sweden, but it is treated as a prescription medicine, which means possession without a valid Swedish prescription is itself an issue independent of the import question.

Why tesamorelin has no EU authorisation

When Theratechnologies, the Canadian developer of Egrifta, sought EU marketing authorisation in the early 2010s, the EMA's Committee for Medicinal Products for Human Use (CHMP) raised two concerns it considered unresolved. First, the committee questioned whether the abdominal-fat reduction demonstrated in the pivotal trials translated into a meaningful clinical benefit for European HIV patients. The trial populations were not judged sufficiently representative of European patients with HIV-associated lipodystrophy. Second, the committee flagged a major safety concern around elevated IGF-1 (insulin-like growth factor 1) levels in treated patients, citing potential links to cancer risk and to diabetic complications^[1]. The applicant withdrew before a formal negative opinion was issued.

The EMA's public assessment report notes that the CHMP had formulated questions, assessed responses, but found unresolved issues remained at the point of withdrawal. That public record explains the current situation more precisely than the simple fact of withdrawal: the CHMP did not consider the benefit-risk balance positive on the data presented. No sponsor has succeeded with a re-application since. As of the publication date of this article, tesamorelin remains unauthorised throughout the EU and EEA, including Sweden.

The consequence for Swedish patients is practical. There is no authorised product to dispense through normal pharmacy channels. No Swedish prescriber can write a standard prescription for tesamorelin at a licensed pharmacy and expect to have it filled from authorised stock.

The named-patient route: narrow but lawful

Swedish law follows the EU framework on unlicensed medicines. Under this framework, a prescribing clinician can request a special licence from Läkemedelsverket to import and supply an unlicensed medicine for a specifically identified patient. This is the named-patient route (in Swedish: licenspreparat for a named individual). The clinician, not the patient, initiates the process and takes clinical and regulatory responsibility for the prescription. If the agency approves the request, a licensed importer sources the product and the patient receives it through a pharmacy supply chain, not through a direct-to-consumer courier from the US.

In practice, this route is designed for situations where no authorised alternative exists for a clinically necessary treatment. A prescribing clinician using the named-patient route in Sweden is responsible for documenting the clinical justification, selecting the appropriate reference product (in this case Egrifta SV, the current US formulation), and monitoring the patient according to the prescribing information of that reference product.

The key point for readers: the named-patient route is not a shortcut for individuals to access a medicine outside the normal authorisation process. It is a supervised mechanism for clinicians to provide care in situations where authorised alternatives are absent. A patient who wants to explore this route in Sweden would need to do so through a clinician willing to take on that responsibility, not by ordering from abroad themselves.

What the approved indication covers, and what it does not

The FDA approved tesamorelin (as Egrifta SV, 1.4 mg subcutaneously once daily) for one specific indication: reduction of excess abdominal fat in HIV-infected adults with lipodystrophy^[3]. Phase-3 trial data showed the drug reduced visceral adipose tissue by roughly 15 to 20 percent over six months in this population and was associated with improvements in metabolic markers in patients who responded to treatment, including triglyceride reductions and better preservation of glucose homeostasis^[4].

The FDA label contraindicates use in active malignancy, pregnancy, known hypersensitivity to tesamorelin, and in patients with disrupted hypothalamic-pituitary axis function (including from surgery, tumours, radiation, or head trauma)^[3]. The label also warns of fluid retention, possible glucose intolerance, and elevations in IGF-1 with effects that the label describes as "unknown" in prolonged use.

The approved indication does not extend to body-composition goals in people without HIV-associated lipodystrophy, to anti-ageing, or to the sleep and recovery purposes sometimes cited in online communities. The trial programme is concentrated in the HIV-lipodystrophy population, and the evidence base for other applications is essentially absent. For the broader tesamorelin profile, including mechanism and safety data, see our main peptide page.

The grey-market reality in Sweden

Research-chemical vendors in jurisdictions outside the EEA do ship peptide-labelled products to Sweden, and some of those products are labelled as tesamorelin or GHRH analogue. The transaction sits outside the EEA medicines import prohibition in the sense that some parcels pass through customs without being identified as medicines. That does not make the import lawful. It reflects detection probability rather than legal permission.

Products sold through those channels are not manufactured to pharmaceutical quality standards, are not subject to the quality oversight the Egrifta supply chain carries, and carry no regulatory guarantee that the labelled content matches what is in the vial. The Swedish Medical Products Agency's position is that any substance classified as a medicine under Swedish law requires compliance with Swedish regulations, which includes the import prohibition and the prescription requirement.

The grey-market activity is visible in community discussions and in the pattern of warning letters the FDA has sent to US compounding pharmacies for producing peptides without approved drug applications. Shipments intended for personal use in Sweden that are intercepted at customs are unlikely to be a criminal matter for the individual in straightforward cases, but the legal position is not zero-risk, and the product-quality risk is independent of the customs risk.

What to do if you are considering tesamorelin in Sweden

If you have HIV-associated lipodystrophy and believe tesamorelin could be clinically appropriate, the route is to discuss the named-patient option with a prescribing clinician who can engage with Läkemedelsverket on your behalf. That is the only lawful route to the product in Sweden.

For all other purposes, the evidence base does not support the off-label uses most commonly discussed online, the import barrier adds a practical layer on top of the clinical uncertainty, and the grey-market quality risk adds a further layer on top of that. Decisions about whether any of that risk profile is appropriate belong with a clinician who knows your medical history, not with an online vendor.

See the regulation section of our tesamorelin page for the per-country picture across the EU and EEA, and our Sweden regulation hub for the broader framework that governs peptides in this country.